CDSCO approves AstraZeneca’s Dapagliflozin with additional indication for treating CKD and heart…
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalisation for heart failure in adults with…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.